Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile
5 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled69 locationsNCT06500702
Recruiting
Phase 3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
Sanofi210 enrolled121 locationsNCT06834347
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Colitis Ulcerative
Sanofi204 enrolled115 locationsNCT06867094
Recruiting
Phase 3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
Sanofi210 enrolled113 locationsNCT06834360
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Crohn's Disease
Sanofi260 enrolled138 locationsNCT06637631
Recruiting
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled166 locationsNCT07190209
Recruiting
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled188 locationsNCT07190222
Recruiting
Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Asthma
Sanofi1,147 enrolled236 locationsNCT06676319
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Dermatitis Atopic
Sanofi390 enrolled146 locationsNCT06241118
Recruiting
Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Dermatitis Atopic
Sanofi901 enrolled175 locationsNCT05769777
Recruiting
Phase 3
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Chronic Inflammatory Demyelinating PolyradiculoneuropathyPolyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi140 enrolled124 locationsNCT06290128